Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: A randomized phase III DeCOG trial

9032 Background: Low-dose Interferon alpha 2a (IFNa2a) is approved for the adjuvant treatment of high-risk malignant melanoma (MM) in Europe. Controversy exists as to the impact of the duration of ...